The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.
GSK’s new drug application for its investigational oral antibiotic gepotidacin has been accepted for priority review by the ...
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents: London, UK Thursday, October 17, 2 ...
On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an ...